A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma

Clinical Lymphoma

Volumn 5, Issue 1, 2004, Pages 50-55

  Levis, Alessandro ^a   Pietrasanta, Daniela ^a   Godio, Laura ^b   Vitolo, Umberto ^b   Ciravegna, Giorgio ^c   Di Vito, Francesco ^d   Gavarotti, Paolo ^e   Guglielmelli, Tommasina ^e   Orsucci, Lorella ^b   Raviolo, Ermanno ^f   Scalabrini, Delia Rota ^g   Salvi, Flavia ^a   Tonso, Anna ^h   Aglietta, Massimo ^g   Boccadoro, Mario ^e   Gallamini, Andrea ^f   Saglio, Giuseppe ^e   Scassa, Enzo ^c   Gallo, Eugenio ^b  

^a C Arrigo Children's Hospital   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Ospedale Civile   (Italy)

^d Ospedale Civile   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f S CROCE E CARLE HOSPITAL   (Italy)

^g Institute of Research Against Cancer   (Italy)

^h OSPEDALE DEGLI INFERMI   (Italy)

Author keywords

Biopsy; Nodal involvement; Prognosis; Staging

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; LOMUSTINE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MIXED CELL LYMPHOMA; MULTIVARIATE ANALYSIS; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM;

EID: 4344656653     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.010     Document Type: Article

References (37)

1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
2. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31:1860-1861.
3. Proctor SJ, Taylor P, Mackie MJ, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma 1992; 7(suppl): 17-20.
4. Gobbi PG, Comelli M, Grignani GE, et al. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica 1994; 79:241-255.
5. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.
6. Webb DI, Ubogy G, Silver RT. Importance of bone marrow biopsy in the clinical staging of Hodgkin's disease. Cancer 1970; 26:313-317.
7. Bartl R, Frisch B, Burkhardt Rea. Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. Brit J Haematol 1982; 51:345-360.
8. Kaplan HS. Hodgkin's Disease: Second Edition. Cambridge: Harvard University Press, 1980.
9. Gupta RK, Godspadorowicz MK, Lister TA. Clinical evaluation and staging of Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V et al., eds. Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999.
10. Macintyre EA, Vaughan Hudson B, Linch DC, et al. The value of staging bone marrow trephine biopsy in Hodgkin's disease. Eur J Haematol 1987; 39:66-70.
11. Munker R, Hasenclever D, Brosteanu O, et al. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol 1995; 13:403-409.
12. Spector N, Nucci M, Oliveira De Morais JC, et al. Clinical factors predictive of bone marrow involvement in Hodgkin's disease. Leuk Lymphoma 1997; 26:171-176.
13. Brunning RD, Bloomfield CD, McKenna RW, et al. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 1975; 82:365-366.
14. Wang J, Weiss LM, Chang KL, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignant. Cancer 2002; 94:1522-1531.
15. Luoni M, Fava S, Declich P. Bone marrow biopsy for staging Hodgkins lymphoma: the value of bilateral or unilateral trephine biopsy. J Clin Oncol 1996; 14:682-683.
16. Young RC, Anderson T, DeVita VT. The treatment of Hodgkin's disease: emphasizing programs at the Clinic Center, National Institutes of Health. Curr Probl Cancer 1977; 1:1-29.
17. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104:739-746.
18. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-259.
19. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience. Ann Oncol 1991; 2:(suppl 2):S55-S62.
20. Bartlett NL, Rosenberg SA, Hoppe RT et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13:1080-1088.
21. Gobbi PG, Pieresca C, Federico M, et al. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. J Clin Oncol 1993; 11:712-719.
22. Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 1988; 41:359-367.
23. Rosenberg SA. Hodgkin's disease of the bone marrow. Cancer Res 1971; 31:1733-1736.
24. Howell SJ, Grey M, Chang J, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002; 119:408-411.
25. O'Carroll DI, McKenna RW, Brunning RD. Bone marrow manifestations of Hodgkin's disease. Cancer 1976; 38:1717-1728.
26. Cimino G, Anselmo AP, De Luca AM, et al. Bone marrow involvement at onset of Hodgkin's disease. Tumori 1983; 69:47-51.
27. Bishop PW, McNally K, Harris M. Audit of bone marrow trephines. J Clin Pathol 1992; 45:1105-1108.
28. Bain BJ. Bone marrow trephine biopsy. J Clin Pathol 2001; 54:737-742.
29. Campbell JK, Matthews JP, Seymour JF, et al. Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Ann Oncol 2003; 14:273-276.
30. Shields AF, Porter BA, Churchley S, et al. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. J Clin Oncol 1987; 5:225-230.
31. Hoane BR, Shields AF, Porter BA, et al. Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood 1991; 78:728-738.
32. Ozguroglu M, Esen Ersavasti G, Demir G, et al. Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma. Pathol Oncol Res 1999; 5:123-128.
33. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9:1117-1122.
34. Partridge S, Timothy A, O'Doherty MJ, et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11:1273-1279.
35. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86:266-273.
36. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91:889-899.
37. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101:3875-3876.